Brilinta 90mg Tablet
Marketer
AstraZeneca
Salt Composition
Ticagrelor (90mg)
Overview Brilinta 90mg Tablet
Ticagrelor 90mg tablets are antiplatelet agents, reducing the risk of harmful blood clot formation within blood vessels. This action helps prevent heart attacks and strokes in patients with coronary artery disease. These tablets are also indicated for individuals who've recently experienced a heart attack or unstable angina and received a coronary stent. They help reduce the likelihood of further cardiac events, including recurrent heart attacks, stroke, and stent thrombosis. Concomitant aspirin therapy is usually prescribed. Ticagrelor 90mg may be administered with or without food, consistently at the same time daily; continuous use is crucial, even during asymptomatic periods. Cessation increases the risk of recurrent cardiac events. The most frequent adverse effect is increased bleeding tendency; injuries may bleed longer than usual, though typically resolving spontaneously. Mild dyspnea may occur, generally subsiding with continued therapy. Report persistent bleeding, worsening or unremitting breathlessness to your physician. Ticagrelor 90mg is contraindicated in individuals with active bleeding (e.g., gastrointestinal ulcers, intracranial hemorrhage) or liver disease. Disclose any such conditions prior to commencing treatment.
Primary Ingredients of Brilinta 90mg Tablet
No information provided. Please provide the text you wish me to rephrase.
Uses of Brilinta 90mg Tablet
Avoiding cardiac arrest and cerebrovascular accidents
Major Benefits of Brilinta 90mg Tablet:
Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the 90mg Brilinta tablet whole; avoid chewing, crushing, or breaking it. This medication can be taken with or without food, although consistent timing is recommended.
Common Side effects of Brilinta 90mg Tablet:
- Bleeding
- Breathlessness
How to use Brilinta 90mg Tablet:
Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the 90mg Brilinta tablet whole; do not crush, chew, or break it. While this medication can be taken with or without food, consistent timing is recommended.
How Brilinta 90mg Tablet works:
Ticagrelor 90mg tablets are prescribed to inhibit platelet aggregation. This action reduces the risk of dangerous clot development, consequently minimizing the likelihood of stroke or myocardial infarction.
SAFETY ADVICE
AlcoholCAUTION
Using Brilinta 90mg Tablets with alcohol requires careful consideration. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Ticagrelor 90mg tablets may pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Data on the compatibility of Brilinta 90mg tablets with breastfeeding are currently lacking. Seek medical advice from your physician.
DrivingSAFE
Driving ability is typically unaffected by taking a 90mg Brilinta tablet.
KidneySAFE IF PRESCRIBED
Ticagrelor 90mg tablets are considered safe for individuals with kidney impairment; no dosage modification is advised. Data regarding ticagrelor 90mg tablet use in patients undergoing renal dialysis is currently limited.
LiverCAUTION
Patients with liver impairment should use Ticagrelor 90mg tablets cautiously; dosage modification may be necessary. Severe liver disease contraindicates the use of Ticagrelor 90mg tablets. Physician consultation is advised.
What if you forget to take Brilinta 90mg Tablet :
Should you forget a Brilinta 90mg Tablet dose, take it immediately. Nevertheless, if your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Brilinta 90mg Tablet
| Label | Value |
|---|---|
| Chemical Type | Triazolopyrimidine derivatives |
| Developing Habits | No. |
| Treatment Category | KINSHIP |
| Behavior Class | ADP receptor antagonists (P2Y12 inhibitors) |




